Clinical Trials
20 trialsNCT04485013 2026-02-18
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
Phase 1 Recruiting
NCT05104567 2025-09-24
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
Sanofi
Phase 2 Completed
NCT03319459 2021-11-22
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Completed
NCT04464967 2021-05-12
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
Phase 1/2 Withdrawn
NCT00439608 2020-02-17
Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer
Brown University
Phase 2 Completed
NCT00398398 2020-01-07
Study of XELOX With Cetuximab in Advanced Gastric Cancer
Asan Medical Center
Phase 2 Completed
NCT02318901 2019-10-21
PembroMab
Western Regional Medical Center
Phase 1/2 Terminated
NCT00477880 2017-01-10
Cetuximab in Treating Patients With Ménétrier Disease at High Risk of Developing Stomach Cancer
Vanderbilt University Medical Center
Phase 1 Completed
NCT01360086 2016-05-30
Fluorouracil, Cisplatin, Leucovorin Calcium, and Cetuximab in Treating Patients With Adenocarcinoma of the Stomach or Gastroesophageal Junction
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT00857246 2015-12-07
Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer
NYU Langone Health
Phase 2 Completed
NCT00397904 2015-11-25
Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00397384 2015-09-30
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00477711 2015-05-19
EXTRA
Peking University
Phase 2 Completed
NCT00130689 2015-05-14
Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00678535 2014-07-21
EXPAND
Merck KGaA, Darmstadt, Germany
Phase 3 Completed
NCT01388790 2013-11-20
Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT01611506 2013-01-09
Combination Chemotherapy, Cetuximab and Radiation for Patients With Localized Gastric Cancer
Centre Hospitalier Universitaire Vaudois
Phase 1/2 Terminated
NCT00275951 2012-11-16
FLAG
National Taiwan University Hospital
Phase 2 Completed
NCT00699881 2009-12-23
STAGE
Fudan University
Phase 2 Completed
NCT00384878 2009-02-09
Study of Cetuximab Plus P-HDFL for the First-Line Treatment of Advanced Gastric Cancer
Far Eastern Memorial Hospital
Phase 2 Unknown